Insider Trading Alert - LGND, NSP And FSLR Traded By Insiders
at The Street - Wed Mar 04, 11:52AM CST
Stocks with insider trader activity include LGND, NSP and FSLR
FSLR: 60.61 (-1.05), NSP: 52.85 (-0.55), LGND: 69.51 (+0.55)
Nasdaq stocks posting largest percentage increases
AP - Tue Mar 03, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
DTSI: 32.74 (-0.89), OREX: 7.10 (-0.91), ANY: 7.00 (+0.45), FCSC: 5.82 (-0.12), STAA: 7.28 (+0.14), LGND: 69.51 (+0.55), NXPI: 98.48 (-0.19), VICR: 14.50 (-0.45), TSRI: 4.63 (-0.24), STRZB: 33.11 (-1.18), SMRT: 12.31 (-0.09), STRZA: 33.35 (-0.72), OMER: 26.14 (-0.21)
Ligand Pharmaceuticals Weakens The Bear Case
Trevor Lowenthal - at Seeking Alpha - Tue Mar 03, 10:17AM CST
LGND: 69.51 (+0.55), AMGN: 154.88 (-4.72), CELG: 118.03 (-2.68)
Ligand Pharmaceuticals (LGND) Jumps: Stock Rises 15.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 8:25AM CST
Ligand Pharmaceuticals (LGND) was a big mover last session, with its shares rising over 15% on the day.
LGND: 69.51 (+0.55), AFFX: 11.81 (-0.38)
Ligand to Present at the 27th Annual Roth Conference on March 9th
Business Wire - Tue Mar 03, 7:30AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John Higgins, Chief Executive Officer of Ligand will present at the 27th Annual Roth Conference on Monday, March 9, 2015 at 2:30 p.m. Pacific (5:30 p.m. Eastern Time). The conference takes place at The Ritz-Carlton in Laguna Niguel, California.
LGND: 69.51 (+0.55)
Ligand up on Kyprolis study
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:05PM CST
AMGN: 154.88 (-4.72), LGND: 69.51 (+0.55)
Discussing The Sale Of Amvona Fund's Stake In World Wrestling Entertainment, Corporate Governance And Other Issues
Amvona - Seeking Alpha - Fri Feb 27, 5:59AM CST
To listen to the full interview, click here: Benzinga - Rev. Emmanuel Lemelson CIO Lemelson Capital - PreMarket Prep. Show (February 20, 2015) On February 20, 2015, Rev. Father Emmanuel Lemelson, Founder and President of The Lantern...
KLIC: 16.11 (+0.05), GEOS: 17.17 (-0.93), WWE: 17.17 (+0.08), LGND: 69.51 (+0.55), AAPL: 126.60 (+0.19), BABA: 84.40 (-1.70)
My Top Biotechnology Stocks For 2015
Stan Stafford - at Seeking Alpha - Thu Feb 19, 8:49AM CST
MDVN: 126.55 (-0.53), CBPO: 82.88 (+1.08), BIIB: 417.63 (-7.98), INSY: 57.69 (+0.08), MYGN: 35.13 (+0.34), PCYC: 254.56 (+0.34), GILD: 101.81 (-1.61), UTHR: 160.65 (-0.71), ALXN: 181.65 (-4.14), LGND: 69.51 (+0.55), ACOR: 34.74 (-0.56), REGN: 422.13 (-6.82), PDLI: 6.70 (-0.40)
Ligand Pharmaceutical (LGND) Upgraded From Hold to Buy
at The Street - Wed Feb 11, 12:40PM CST
Ligand Pharmaceutical (LGND) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
LGND: 69.51 (+0.55)
Ligand Pharmaceuticals Had Strong 2014, Shares Barely Moved, Time To Act
Chris Katje - at Seeking Alpha - Tue Feb 10, 3:24PM CST
LGND: 69.51 (+0.55)
Ritter Pharmaceuticals elects Matthew W. Foehr to board
M2 - Tue Feb 10, 5:58AM CST
Pharmaceutical company Ritter Pharmaceuticals revealed on Monday the addition of Matthew W. Foehr to its board of directors to increase its directors to five.
LGND: 69.51 (+0.55)
Glaxo Submits Another Revolade Application in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:54PM CST
GlaxoSmithKline (GSK) announced that it has submitted another marketing application for Revolade in the EU.
AGN: 233.51 (-1.90), LGND: 69.51 (+0.55), GSK: 46.73 (-0.87)
Ligand Pharmaceuticals' (LGND) CEO John Higgins on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 09, 12:57PM CST
LGND: 69.51 (+0.55)
Ligand Pharmaceuticals (LGND) Posts In-Line Q4 Earnings - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 9:03AM CST
Ligand Pharmaceuticals (LGND) Posts In-Line Q4 Earnings
LGND: 69.51 (+0.55)
Ligand meets 4Q profit forecasts
Automated Insights - Mon Feb 09, 7:48AM CST
LA JOLLA, Calif. (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Monday reported fourth-quarter profit of $7.1 million.
LGND: 69.51 (+0.55)
Ligand Pharmaceuticals EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 7:34AM CST
LGND: 69.51 (+0.55)
Ligand Reports Fourth Quarter and Full Year 2014 Financial Results
Business Wire - Mon Feb 09, 7:31AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and 12 months ended December 31, 2014, and provided an operating forecast and program updates.
LGND: 69.51 (+0.55)
Ritter Pharmaceuticals Names Matthew W. Foehr to Its Board of Directors
Business Wire - Mon Feb 09, 6:00AM CST
Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company focused on gastrointestinal disorders, announces the appointment of Matthew W. Foehr to the Company's Board of Directors. Mr. Foehr is President and Chief Operating Officer of Ligand Pharmaceuticals (NASDAQ: LGND) and his appointment expands Ritter's Board membership to five Directors.
LGND: 69.51 (+0.55)
Ligand seeks additional indication for ITP drug Revolade from European Medicines Agency
M2 - Mon Feb 09, 5:54AM CST
Biopharmaceutical company Ligand Pharmaceuticals (NasdaqGM:LGND) disclosed on Friday the submission of data to the European Medicines Agency (EMA) of a variation to the Marketing Authorization for eltrombopag (Revolade) seeking an additional indication for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).
LGND: 69.51 (+0.55), GSK: 46.73 (-0.87)